Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADME study of radiolabeled HDM201 in healthy adults
NL-OMON49451Active, not recruiting
- Sponsor
- Novartis
- Start
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of siremadlin in cancer, sponsored by Novartis. Primary endpoints: Routes and rates of excretion and mass balance, Pharmacokinetics of total radioactivity in blood and plasma and 1 more. Started Jul 2020; status: active, not recruiting.
02
Drugs
siremadlin
03
Conditions
cancer
Beyond the preview
Go deeper on NL-OMON49451.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49451.